ストックスクリーナーアプリを入手
1.81
4.23%
-0.08
前日終値:
$1.89
開ける：
$1.96
24時間の取引高:
952.90K
Relative Volume:
1.71
時価総額：
$56.46M
収益：
$1.05M
当期純損益:
$-48.82M
株価収益率:
-0.9891
EPS:
-1.83
ネットキャッシュフロー:
$-47.49M
1週間 パフォーマンス:
+16.77%
1か月 パフォーマンス:
+64.55%
6か月 パフォーマンス:
+0.56%
1年 パフォーマンス:
-76.88%
1日の値動き範囲:
$1.76
$1.98
1週間の範囲:
$1.40
$2.41
52週間の値動き範囲:
$1.06
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
名前
Actinium Pharmaceuticals Inc
セクター
電話
646-767-3870
住所
275 Madison Avenue, 7th Floor, New York, NY
ATNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.81 | 56.46M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-02-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 開始されました | B. Riley Securities | Buy |
| 2020-11-05 | 開始されました | Alliance Global Partners | Buy |
| 2017-12-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-14 | 開始されました | Maxim Group | Buy |
| 2016-08-25 | 開始されました | ROTH Capital | Buy |
| 2016-02-29 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2014-10-01 | 開始されました | MLV & Co | Buy |
| 2014-07-22 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
ATNM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. Investors - TradingView
Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit - PR Newswire
Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Actinium - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - TradingView
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView
Actinium Pharmaceuticals unveils non-PSMA-targeting Ac-225 radiotherapy for prostate cancer - BioWorld Online
Actinium Pharmaceuticals secures Ac-225 supply from Eckert & Ziegler - DOTmed HealthCare Business News
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) - Business Wire
Breakthrough: New Prostate Cancer Treatment Achieves Near-Complete Tumor Elimination in Preclinical Study - StockTitan
Actinium Pharmaceuticals unveils novel prostate cancer therapy - Investing.com
Game-Changing Cancer Treatment: Actinium's New Non-PSMA Therapy Targets $50B+ Market - StockTitan
Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago - Endpoints News
Actinium rises ahead of presentation at Trump Mar-a-Lago Club - MSN
Actinium stock rises ahead of Mar-a-Lago event (ATNM:NYSE) - Seeking Alpha
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - PR Newswire
Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at HC Wainwright - Defense World
Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event - Stocks Telegraph
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - StockTitan
Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities - Marketscreener.com
Major Breakthrough: Actinium Locks Critical Supply Deal for Revolutionary Cancer Treatment Development - StockTitan
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateATNM - ACCESS Newswire
Major Cancer Breakthrough: Actinium and MSK Join Forces to Transform AML Treatment Landscape - StockTitan
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Cl - Longview News-Journal
Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination - Yahoo Finance
Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy - Marketscreener.com
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO - Longview News-Journal
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia - Longview News-Journal
Game-Changing Leukemia Treatment Extends Survival 6x Longer Than Standard Therapy - StockTitan
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts - Defense World
HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference - Citizentribune
Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - StockTitan
Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI - Marketscreener.com
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PR Newswire
Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients - StockTitan
Actinium Pharmaceuticals stock hits 52-week low at $1.07 By Investing.com - Investing.com Canada
BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World
Actinium Pharmaceuticals stock hits 52-week low at $1.1 - MSN
25,000 Shares in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Purchased by Vontobel Holding Ltd. - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 4.5% – What’s Next? - Defense World
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
Actinium Pharmaceuticals Inc (ATNM) vs. Its Peers: A Comparison - The News Heater
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Barclays PLC Buys 32,784 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis - MarketBeat
Actinium Pharmaceuticals Inc (ATNM) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):